Technical Analysis for RARE - Ultragenyx Pharmaceutical Inc.
Grade | Last Price | % Change | Price Change |
---|---|---|---|
C | 44.24 | 0.89% | 0.39 |
Earnings due: May 2
*** please verify all earnings dates ***ADX | Long Term | Intermediate Term | Short Term |
---|---|---|---|
Strong | Up | Down | Up |
Date | Alert Name | Type | % Chg |
---|---|---|---|
NR7 | Range Contraction | 0.00% | |
NR7-2 | Range Contraction | 0.00% | |
Narrow Range Bar | Range Contraction | 0.00% | |
New Downtrend | Bearish | 0.89% | |
NR7 | Range Contraction | 0.89% | |
Gapped Down | Weakness | 0.89% | |
Non-ADX 1,2,3,4 Bearish | Bearish Swing Setup | -0.09% | |
Inside Day | Range Contraction | -0.09% | |
Oversold Stochastic | Weakness | -1.93% | |
Slingshot Bearish | Bearish Swing Setup | 1.26% |
Alert | Time |
---|---|
Possible NR7 | about 19 hours ago |
Up 1% | about 23 hours ago |
Rose Above Previous Day's High | about 23 hours ago |
Rose Above 10 DMA | about 23 hours ago |
Possible NR7 | 2 days ago |
Get a Trading Sidekick!
- Earnings date: 05/02/2024
Ultragenyx Pharmaceutical Inc. Description
Ultragenyx Pharmaceutical Inc., a development-stage biotechnology company, focuses on the identification, acquisition, development, and commercialization of various products for the treatment of rare and ultra-rare diseases in the United States. It develops various biologics product candidates, including KRN23, a human monoclonal antibody to bind and reduce the biological activity of fibroblast growth factor to enhance abnormally low phosphate levels in patients with X-linked hypophosphatemia; recombinant human beta-glucuronidase, an intravenous enzyme replacement therapy for the treatment of mucopolysaccharidosis 7; and recombinant human protective protein cathepsin-A, an enzyme replacement therapy for galactosialidosis. The company is also developing a range of small-molecule product candidates comprising triheptanoin, a substrate replacement therapy for patients with fatty acid oxidation disorders, as well as for patients with glucose transporter type-1 deficiency syndrome; and oral formulation of sialic acid to treat hereditary inclusion body myopathy. It has license agreements with AAI Pharma Services Corp. and HIBM Research Group; and a collaboration and license agreement with Nobelpharma Co., Ltd. The company was founded in 2010 and is headquartered in Novato, California.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Biopharmaceutical Life Sciences Acid Pharmacy Rare Diseases Monoclonal Antibody Phosphates Glucose Fatty Acids Fibroblast Growth Factor Myopathy Transporter Molecule Product Enzyme Replacement Therapy Mucopolysaccharidosis Biologics Deficiency Syndrome Pharma Services
Indicator | Bull Case | Neutral / Hold | Bear Case |
---|---|---|---|
50 DMA | |||
200 DMA | |||
ADX Trend | |||
Oversold / Overbought | |||
Relative Strength |
Indicator | Value |
---|---|
52 Week High | 54.98 |
52 Week Low | 31.52 |
Average Volume | 717,631 |
200-Day Moving Average | 42.13 |
50-Day Moving Average | 47.79 |
20-Day Moving Average | 46.21 |
10-Day Moving Average | 43.62 |
Average True Range | 2.08 |
RSI (14) | 43.82 |
ADX | 25.27 |
+DI | 17.05 |
-DI | 28.23 |
Chandelier Exit (Long, 3 ATRs) | 46.32 |
Chandelier Exit (Short, 3 ATRs) | 47.31 |
Upper Bollinger Bands | 52.18 |
Lower Bollinger Band | 40.25 |
Percent B (%b) | 0.33 |
BandWidth | 25.81 |
MACD Line | -1.09 |
MACD Signal Line | -0.91 |
MACD Histogram | -0.1851 |
Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
---|---|---|---|---|---|
Resistance 4 (R4) | 45.54 | ||||
Resistance 3 (R3) | 45.51 | 45.04 | 45.32 | ||
Resistance 2 (R2) | 45.04 | 44.71 | 45.06 | 45.25 | |
Resistance 1 (R1) | 44.64 | 44.51 | 44.84 | 44.67 | 45.18 |
Pivot Point | 44.18 | 44.18 | 44.28 | 44.19 | 44.18 |
Support 1 (S1) | 43.78 | 43.84 | 43.98 | 43.81 | 43.30 |
Support 2 (S2) | 43.31 | 43.64 | 43.33 | 43.23 | |
Support 3 (S3) | 42.91 | 43.31 | 43.16 | ||
Support 4 (S4) | 42.94 |